Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Transplant. Dec 24, 2013; 3(4): 62-67
Published online Dec 24, 2013. doi: 10.5500/wjt.v3.i4.62
Published online Dec 24, 2013. doi: 10.5500/wjt.v3.i4.62
Clinical and ethical considerations of massively parallel sequencing in transplantation science
Andreas Scherer, Spheromics, 81100 Kontiolahti, Finland
Author contributions: Scherer A solely contributed to this paper.
Correspondence to: Andreas Scherer, PhD, APM, CEO, Spheromics, Lehmustie 16, 81100 Kontiolahti, Finland. andreas.scherer@spheromics.com
Telephone: +358-44-3629559 Fax: +358-44-3629559
Received: June 25, 2013
Revised: September 12, 2013
Accepted: October 11, 2013
Published online: December 24, 2013
Revised: September 12, 2013
Accepted: October 11, 2013
Published online: December 24, 2013
Core Tip
Core tip: Despite the great excitement about the opportunities that massively parallel sequencing (MPS) bears for the promotion of, e.g., transplant science, personalized medicine faces the challenge to guarantee privacy of data and findings. Here, some applications of MPS in transplant science are mentioned, and concerns and challenges in data analysis and management are discussed.